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Methods. We used data from the Influenza Hospitalization Surveillance Network (FluSurv-NET), a population-based system, to describe pregnant women aged 15-44 years hospitalized with community-acquired, laboratory-confirmed influenza during the 2010-11 through 2012-13 influenza seasons. Severe influenza was defined by intensive care unit (ICU) admission or death. We compared women's characteristics using χ 2 and Fisher's exact tests, and rank sum tests for differences in medians. Results. During the study period, 631 pregnant women were identified. The median age was 27 years (interquartile range [IQR] , 23-31). The majority of women (70%) had no underlying medical conditions other than pregnancy, and 20% had asthma (most common underlying condition). Overall, 356 (56%) were in the third trimester of gestation; 138 (22%) delivered during hospitalization, with 34/138 (25%) preterm births (<37 weeks gestation). Overall, 526 women (83%) were treated with antivirals; those treated were more likely to have a positive rapid influenza test than those not treated (54% vs.33%, p <0.01). Twenty-five women (4%) had severe influenza (22 ICU admissions, 3 deaths). Those who died received antiviral treatment ≥3 days after illness onset. Women treated early (i.e., within the first day of admission) had a shorter median length of stay (LOS) (2 days [IQR 1-3]) than those treated after day 1 (5 days , p < 0.01). Among severe cases, those treated early also had a shorter median LOS (6 days [IQR 2-11]) than those treated later (9 days , p = 0.21). A minority of women (26%) received influenza vaccine for the season.
Conclusion. Our findings suggest that prompt antiviral treatment for pregnant women hospitalized with influenza may reduce LOS. Influenza during pregnancy is associated with maternal and infant morbidity and annual influenza vaccination is warranted. Physicians should not wait for laboratory test results when influenza is suspected to initiate treatment.
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